View Financial HealthAnGes 배당 및 자사주 매입배당 기준 점검 0/6AnGes 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-29.8%자사주 매입 수익률총 주주 수익률-29.8%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • May 09First quarter 2026 earnings released: JP¥2.74 loss per share (vs JP¥3.98 loss in 1Q 2025)First quarter 2026 results: JP¥2.74 loss per share (improved from JP¥3.98 loss in 1Q 2025). Revenue: JP¥203.0m (up 20% from 1Q 2025). Net loss: JP¥1.08b (loss narrowed 13% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.공시 • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026Board Change • Apr 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 1 highly experienced director. CEO, President & Representative Director Ei Yamada is the most experienced director on the board, commencing their role in 2001. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Mar 26Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis PatientsVasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.New Risk • Feb 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.9b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥4.9b free cash flow). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).Reported Earnings • Feb 11Full year 2025 earnings released: JP¥14.44 loss per share (vs JP¥120 loss in FY 2024)Full year 2025 results: JP¥14.44 loss per share (improved from JP¥120 loss in FY 2024). Revenue: JP¥874.0m (up 36% from FY 2024). Net loss: JP¥5.12b (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.공시 • Feb 10AnGes, Inc., Annual General Meeting, Mar 27, 2026AnGes, Inc., Annual General Meeting, Mar 27, 2026.공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026Reported Earnings • Nov 09Third quarter 2025 earnings released: JP¥1.93 loss per share (vs JP¥15.06 loss in 3Q 2024)Third quarter 2025 results: JP¥1.93 loss per share (improved from JP¥15.06 loss in 3Q 2024). Revenue: JP¥232.0m (up 87% from 3Q 2024). Net loss: JP¥722.0m (loss narrowed 80% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.공시 • Sep 04Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis PatientsA groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.공시 • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025Reported Earnings • Aug 10Second quarter 2025 earnings released: JP¥7.91 loss per share (vs JP¥7.54 loss in 2Q 2024)Second quarter 2025 results: JP¥7.91 loss per share (further deteriorated from JP¥7.54 loss in 2Q 2024). Revenue: JP¥245.0m (up 4.7% from 2Q 2024). Net loss: JP¥2.72b (loss widened 62% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.New Risk • Jul 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥6.7b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥6.7b free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risk Revenue is less than US$5m (JP¥699m revenue, or US$4.7m).공시 • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025Reported Earnings • May 10First quarter 2025 earnings released: JP¥3.98 loss per share (vs JP¥9.14 loss in 1Q 2024)First quarter 2025 results: JP¥3.98 loss per share (improved from JP¥9.14 loss in 1Q 2024). Revenue: JP¥169.0m (up 50% from 1Q 2024). Net loss: JP¥1.25b (loss narrowed 32% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 05Full year 2024 earnings released: JP¥120 loss per share (vs JP¥39.29 loss in FY 2023)Full year 2024 results: JP¥120 loss per share (further deteriorated from JP¥39.29 loss in FY 2023). Revenue: JP¥643.0m (up 323% from FY 2023). Net loss: JP¥28.1b (loss widened 278% from FY 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. External Independent Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025New Risk • Feb 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥6.7b free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Revenue is less than US$5m (JP¥643m revenue, or US$4.3m).Reported Earnings • Feb 16Full year 2024 earnings released: JP¥120 loss per share (vs JP¥39.29 loss in FY 2023)Full year 2024 results: JP¥120 loss per share (further deteriorated from JP¥39.29 loss in FY 2023). Revenue: JP¥643.0m (up 323% from FY 2023). Net loss: JP¥28.1b (loss widened 278% from FY 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.공시 • Feb 14AnGes, Inc., Annual General Meeting, Mar 28, 2025AnGes, Inc., Annual General Meeting, Mar 28, 2025.New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.9b free cash flow). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (JP¥521m revenue, or US$3.3m). Market cap is less than US$100m (JP¥14.4b market cap, or US$92.2m).공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025New Risk • Nov 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥8.9b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.9b free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Revenue is less than US$5m (JP¥521m revenue, or US$3.4m). Market cap is less than US$100m (JP¥11.8b market cap, or US$77.2m).공시 • Aug 27AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024AnGes, Inc. announced that they will report Q3, 2024 results on Nov 08, 2024Reported Earnings • Aug 14Second quarter 2024 earnings released: JP¥7.54 loss per share (vs JP¥10.25 loss in 2Q 2023)Second quarter 2024 results: JP¥7.54 loss per share (improved from JP¥10.25 loss in 2Q 2023). Net loss: JP¥1.68b (loss narrowed 13% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.8b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (JP¥249m revenue, or US$1.6m). Market cap is less than US$100m (JP¥11.7b market cap, or US$74.8m).공시 • Jun 02AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024AnGes, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024Reported Earnings • May 12First quarter 2024 earnings released: JP¥9.14 loss per share (vs JP¥15.91 loss in 1Q 2023)First quarter 2024 results: JP¥9.14 loss per share (improved from JP¥15.91 loss in 1Q 2023). Net loss: JP¥1.82b (loss narrowed 37% from 1Q 2023).공시 • Mar 23AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024AnGes, Inc. announced that they will report Q1, 2024 results on May 10, 2024공시 • Mar 20AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald EuropeAnGes, Inc. announced a private placement of 1st unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥1,300,000,000, 2nd unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥32,500,000, and 300,301 stock acquisition rights at a price of ¥53 per stock acquisition right for gross proceeds of ¥15,915,953, for aggregate gross proceeds of ¥1,348,415,953 on March 19, 2024. The transaction for 1st bonds is expected to close on April 5, 2024, 2nd bonds on October 7, 2024, and stock acquisition rights on April 5, 2024. The transaction included participation from new investor Cantor Fitzgerald Europe.New Risk • Feb 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.8b free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (JP¥152m revenue, or US$1.0m).Reported Earnings • Feb 11Full year 2023 earnings released: JP¥37.17 loss per share (vs JP¥94.29 loss in FY 2022)Full year 2023 results: JP¥37.17 loss per share (improved from JP¥94.29 loss in FY 2022). Net loss: JP¥7.04b (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.공시 • Feb 11AnGes, Inc., Annual General Meeting, Mar 28, 2024AnGes, Inc., Annual General Meeting, Mar 28, 2024.공시 • Jan 19Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanEiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL). Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years (p<0.0001) in children and young adults with HGPS.New Risk • Dec 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.1b (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥10.0b free cash flow). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (JP¥124m revenue, or US$854k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥14.1b market cap, or US$97.2m).공시 • Dec 05AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024AnGes, Inc. announced that they will report fiscal year 2023 results on Feb 09, 2024공시 • Nov 15Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a StudyVasomune Therapeutics, Inc. announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study. About AV-001: Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with COVID-19, influenza, bacterial sepsis, acute kidney injury, glaucoma, hemorrhagic shock, sepsis, stroke, and complications associated with diabetes. Importantly, in multiple pre-clinical studies, AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival.Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: JP¥0.17 (vs JP¥18.09 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥0.17 (up from JP¥18.09 loss in 3Q 2022). Net income: JP¥32.0m (up JP¥2.80b from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 59% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 10Second quarter 2023 earnings released: JP¥10.25 loss per share (vs JP¥29.31 loss in 2Q 2022)Second quarter 2023 results: JP¥10.25 loss per share (improved from JP¥29.31 loss in 2Q 2022). Net loss: JP¥1.92b (loss narrowed 57% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.공시 • Jul 13AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.On July 12, 2023, AnGes, Inc. closed the transaction.New Risk • Jun 29New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 39% per year over the past 5 years. Revenue is less than US$1m (JP¥68m revenue, or US$472k). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding).공시 • Jun 27AnGes, Inc. announced that it expects to receive ¥8.481467 million in fundingAnGes, Inc. announced a private placement to issue 446,393 43rd stock acquisition right at an issue price of ¥19 per right for the gross proceeds of ¥8,481,467 on June 26, 2023. The transaction will include participation from new investor BofA Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on July 12, 2023.공시 • May 28AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023AnGes, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023Reported Earnings • May 12First quarter 2023 earnings released: JP¥15.91 loss per share (vs JP¥19.19 loss in 1Q 2022)First quarter 2023 results: JP¥15.91 loss per share (improved from JP¥19.19 loss in 1Q 2022). Net loss: JP¥2.91b (flat on 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has fallen by 59% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 12Full year 2022 earnings released: JP¥94.29 loss per share (vs JP¥92.85 loss in FY 2021)Full year 2022 results: JP¥94.29 loss per share (further deteriorated from JP¥92.85 loss in FY 2021). Net loss: JP¥14.7b (loss widened 7.6% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 40% per year.공시 • Dec 28AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023AnGes, Inc. announced that they will report fiscal year 2022 results on Feb 10, 2023Reported Earnings • Nov 17Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)Third quarter 2022 results: JP¥18.09 loss per share (improved from JP¥29.39 loss in 3Q 2021). Net loss: JP¥2.77b (loss narrowed 39% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 40% per year and the company’s share price has also fallen by 40% per year.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 10Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)Third quarter 2022 results: JP¥18.09 loss per share (improved from JP¥29.39 loss in 3Q 2021). Net loss: JP¥2.77b (loss narrowed 39% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 40% per year and the company’s share price has also fallen by 40% per year.Reported Earnings • Aug 11Second quarter 2022 earnings released: JP¥29.31 loss per share (vs JP¥27.72 loss in 2Q 2021)Second quarter 2022 results: JP¥29.31 loss per share (down from JP¥27.72 loss in 2Q 2021). Net loss: JP¥4.49b (loss widened 8.5% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.Reported Earnings • May 11First quarter 2022 earnings released: JP¥19.19 loss per share (vs JP¥24.82 loss in 1Q 2021)First quarter 2022 results: JP¥19.19 loss per share (up from JP¥24.82 loss in 1Q 2021). Net loss: JP¥2.94b (loss narrowed 11% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥92.85 loss per share (down from JP¥35.32 loss in FY 2020). Net loss: JP¥13.7b (loss widened 225% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 07Third quarter 2021 earnings released: JP¥29.39 loss per share (vs JP¥10.39 loss in 3Q 2020)Third quarter 2021 results: Net loss: JP¥4.50b (loss widened 252% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Reported Earnings • Aug 09Second quarter 2021 earnings released: JP¥27.72 loss per share (vs JP¥8.06 loss in 2Q 2020)Second quarter 2021 results: Net loss: JP¥4.14b (loss widened 323% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.Reported Earnings • May 12First quarter 2021 earnings released: JP¥24.82 loss per share (vs JP¥8.55 loss in 1Q 2020)First quarter 2021 results: Net loss: JP¥3.31b (loss widened 261% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.Reported Earnings • Apr 06Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)Full year 2020 results: Net loss: JP¥4.21b (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Feb 20New 90-day low: JP¥1,156The company is down 18% from its price of JP¥1,406 on 20 November 2020. The Japanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.Reported Earnings • Feb 17Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)Full year 2020 results: Net loss: JP¥4.21b (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 4563 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 4563 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장AnGes 배당 수익률 vs 시장4563의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (4563)n/a시장 하위 25% (JP)1.7%시장 상위 25% (JP)3.7%업계 평균 (Biotechs)1.3%분석가 예측 (4563) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 4563 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 4563 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 4563 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 4563 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YJP 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 04:35종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AnGes, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kiyokazu YamazakiIchiyoshi Research Institute Inc.Toshiyuki IwataMizuho Securities Co., Ltd.Shinichiro MuraokaMorgan Stanley
Reported Earnings • May 09First quarter 2026 earnings released: JP¥2.74 loss per share (vs JP¥3.98 loss in 1Q 2025)First quarter 2026 results: JP¥2.74 loss per share (improved from JP¥3.98 loss in 1Q 2025). Revenue: JP¥203.0m (up 20% from 1Q 2025). Net loss: JP¥1.08b (loss narrowed 13% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
공시 • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026
Board Change • Apr 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. 1 highly experienced director. CEO, President & Representative Director Ei Yamada is the most experienced director on the board, commencing their role in 2001. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Mar 26Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis PatientsVasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.
New Risk • Feb 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥4.9b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥4.9b free cash flow). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).
Reported Earnings • Feb 11Full year 2025 earnings released: JP¥14.44 loss per share (vs JP¥120 loss in FY 2024)Full year 2025 results: JP¥14.44 loss per share (improved from JP¥120 loss in FY 2024). Revenue: JP¥874.0m (up 36% from FY 2024). Net loss: JP¥5.12b (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
공시 • Feb 10AnGes, Inc., Annual General Meeting, Mar 27, 2026AnGes, Inc., Annual General Meeting, Mar 27, 2026.
공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026
Reported Earnings • Nov 09Third quarter 2025 earnings released: JP¥1.93 loss per share (vs JP¥15.06 loss in 3Q 2024)Third quarter 2025 results: JP¥1.93 loss per share (improved from JP¥15.06 loss in 3Q 2024). Revenue: JP¥232.0m (up 87% from 3Q 2024). Net loss: JP¥722.0m (loss narrowed 80% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
공시 • Sep 04Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis PatientsA groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.
공시 • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025
Reported Earnings • Aug 10Second quarter 2025 earnings released: JP¥7.91 loss per share (vs JP¥7.54 loss in 2Q 2024)Second quarter 2025 results: JP¥7.91 loss per share (further deteriorated from JP¥7.54 loss in 2Q 2024). Revenue: JP¥245.0m (up 4.7% from 2Q 2024). Net loss: JP¥2.72b (loss widened 62% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.
New Risk • Jul 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥6.7b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥6.7b free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risk Revenue is less than US$5m (JP¥699m revenue, or US$4.7m).
공시 • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025
Reported Earnings • May 10First quarter 2025 earnings released: JP¥3.98 loss per share (vs JP¥9.14 loss in 1Q 2024)First quarter 2025 results: JP¥3.98 loss per share (improved from JP¥9.14 loss in 1Q 2024). Revenue: JP¥169.0m (up 50% from 1Q 2024). Net loss: JP¥1.25b (loss narrowed 32% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 05Full year 2024 earnings released: JP¥120 loss per share (vs JP¥39.29 loss in FY 2023)Full year 2024 results: JP¥120 loss per share (further deteriorated from JP¥39.29 loss in FY 2023). Revenue: JP¥643.0m (up 323% from FY 2023). Net loss: JP¥28.1b (loss widened 278% from FY 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. External Independent Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025
New Risk • Feb 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥6.7b free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Revenue is less than US$5m (JP¥643m revenue, or US$4.3m).
Reported Earnings • Feb 16Full year 2024 earnings released: JP¥120 loss per share (vs JP¥39.29 loss in FY 2023)Full year 2024 results: JP¥120 loss per share (further deteriorated from JP¥39.29 loss in FY 2023). Revenue: JP¥643.0m (up 323% from FY 2023). Net loss: JP¥28.1b (loss widened 278% from FY 2023). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
공시 • Feb 14AnGes, Inc., Annual General Meeting, Mar 28, 2025AnGes, Inc., Annual General Meeting, Mar 28, 2025.
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.9b free cash flow). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (JP¥521m revenue, or US$3.3m). Market cap is less than US$100m (JP¥14.4b market cap, or US$92.2m).
공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025
New Risk • Nov 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥8.9b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.9b free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (27% increase in shares outstanding). Revenue is less than US$5m (JP¥521m revenue, or US$3.4m). Market cap is less than US$100m (JP¥11.8b market cap, or US$77.2m).
공시 • Aug 27AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024AnGes, Inc. announced that they will report Q3, 2024 results on Nov 08, 2024
Reported Earnings • Aug 14Second quarter 2024 earnings released: JP¥7.54 loss per share (vs JP¥10.25 loss in 2Q 2023)Second quarter 2024 results: JP¥7.54 loss per share (improved from JP¥10.25 loss in 2Q 2023). Net loss: JP¥1.68b (loss narrowed 13% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.8b free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (JP¥249m revenue, or US$1.6m). Market cap is less than US$100m (JP¥11.7b market cap, or US$74.8m).
공시 • Jun 02AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024AnGes, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024
Reported Earnings • May 12First quarter 2024 earnings released: JP¥9.14 loss per share (vs JP¥15.91 loss in 1Q 2023)First quarter 2024 results: JP¥9.14 loss per share (improved from JP¥15.91 loss in 1Q 2023). Net loss: JP¥1.82b (loss narrowed 37% from 1Q 2023).
공시 • Mar 23AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024AnGes, Inc. announced that they will report Q1, 2024 results on May 10, 2024
공시 • Mar 20AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald EuropeAnGes, Inc. announced a private placement of 1st unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥1,300,000,000, 2nd unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥32,500,000, and 300,301 stock acquisition rights at a price of ¥53 per stock acquisition right for gross proceeds of ¥15,915,953, for aggregate gross proceeds of ¥1,348,415,953 on March 19, 2024. The transaction for 1st bonds is expected to close on April 5, 2024, 2nd bonds on October 7, 2024, and stock acquisition rights on April 5, 2024. The transaction included participation from new investor Cantor Fitzgerald Europe.
New Risk • Feb 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥8.8b free cash flow). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Earnings have declined by 28% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (JP¥152m revenue, or US$1.0m).
Reported Earnings • Feb 11Full year 2023 earnings released: JP¥37.17 loss per share (vs JP¥94.29 loss in FY 2022)Full year 2023 results: JP¥37.17 loss per share (improved from JP¥94.29 loss in FY 2022). Net loss: JP¥7.04b (loss narrowed 52% from FY 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
공시 • Feb 11AnGes, Inc., Annual General Meeting, Mar 28, 2024AnGes, Inc., Annual General Meeting, Mar 28, 2024.
공시 • Jan 19Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanEiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL). Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years (p<0.0001) in children and young adults with HGPS.
New Risk • Dec 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.1b (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥10.0b free cash flow). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (JP¥124m revenue, or US$854k). Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥14.1b market cap, or US$97.2m).
공시 • Dec 05AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024AnGes, Inc. announced that they will report fiscal year 2023 results on Feb 09, 2024
공시 • Nov 15Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a StudyVasomune Therapeutics, Inc. announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study. About AV-001: Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with COVID-19, influenza, bacterial sepsis, acute kidney injury, glaucoma, hemorrhagic shock, sepsis, stroke, and complications associated with diabetes. Importantly, in multiple pre-clinical studies, AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival.
Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: JP¥0.17 (vs JP¥18.09 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥0.17 (up from JP¥18.09 loss in 3Q 2022). Net income: JP¥32.0m (up JP¥2.80b from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 59% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 10Second quarter 2023 earnings released: JP¥10.25 loss per share (vs JP¥29.31 loss in 2Q 2022)Second quarter 2023 results: JP¥10.25 loss per share (improved from JP¥29.31 loss in 2Q 2022). Net loss: JP¥1.92b (loss narrowed 57% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
공시 • Jul 13AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.On July 12, 2023, AnGes, Inc. closed the transaction.
New Risk • Jun 29New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 39% per year over the past 5 years. Revenue is less than US$1m (JP¥68m revenue, or US$472k). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding).
공시 • Jun 27AnGes, Inc. announced that it expects to receive ¥8.481467 million in fundingAnGes, Inc. announced a private placement to issue 446,393 43rd stock acquisition right at an issue price of ¥19 per right for the gross proceeds of ¥8,481,467 on June 26, 2023. The transaction will include participation from new investor BofA Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on July 12, 2023.
공시 • May 28AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023AnGes, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023
Reported Earnings • May 12First quarter 2023 earnings released: JP¥15.91 loss per share (vs JP¥19.19 loss in 1Q 2022)First quarter 2023 results: JP¥15.91 loss per share (improved from JP¥19.19 loss in 1Q 2022). Net loss: JP¥2.91b (flat on 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has fallen by 59% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 12Full year 2022 earnings released: JP¥94.29 loss per share (vs JP¥92.85 loss in FY 2021)Full year 2022 results: JP¥94.29 loss per share (further deteriorated from JP¥92.85 loss in FY 2021). Net loss: JP¥14.7b (loss widened 7.6% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 40% per year.
공시 • Dec 28AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023AnGes, Inc. announced that they will report fiscal year 2022 results on Feb 10, 2023
Reported Earnings • Nov 17Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)Third quarter 2022 results: JP¥18.09 loss per share (improved from JP¥29.39 loss in 3Q 2021). Net loss: JP¥2.77b (loss narrowed 39% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 40% per year and the company’s share price has also fallen by 40% per year.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 10Third quarter 2022 earnings released: JP¥18.09 loss per share (vs JP¥29.39 loss in 3Q 2021)Third quarter 2022 results: JP¥18.09 loss per share (improved from JP¥29.39 loss in 3Q 2021). Net loss: JP¥2.77b (loss narrowed 39% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 40% per year and the company’s share price has also fallen by 40% per year.
Reported Earnings • Aug 11Second quarter 2022 earnings released: JP¥29.31 loss per share (vs JP¥27.72 loss in 2Q 2021)Second quarter 2022 results: JP¥29.31 loss per share (down from JP¥27.72 loss in 2Q 2021). Net loss: JP¥4.49b (loss widened 8.5% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 11First quarter 2022 earnings released: JP¥19.19 loss per share (vs JP¥24.82 loss in 1Q 2021)First quarter 2022 results: JP¥19.19 loss per share (up from JP¥24.82 loss in 1Q 2021). Net loss: JP¥2.94b (loss narrowed 11% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Kimiko Murofushi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥92.85 loss per share (down from JP¥35.32 loss in FY 2020). Net loss: JP¥13.7b (loss widened 225% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 07Third quarter 2021 earnings released: JP¥29.39 loss per share (vs JP¥10.39 loss in 3Q 2020)Third quarter 2021 results: Net loss: JP¥4.50b (loss widened 252% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 09Second quarter 2021 earnings released: JP¥27.72 loss per share (vs JP¥8.06 loss in 2Q 2020)Second quarter 2021 results: Net loss: JP¥4.14b (loss widened 323% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
Reported Earnings • May 12First quarter 2021 earnings released: JP¥24.82 loss per share (vs JP¥8.55 loss in 1Q 2020)First quarter 2021 results: Net loss: JP¥3.31b (loss widened 261% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 06Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)Full year 2020 results: Net loss: JP¥4.21b (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Feb 20New 90-day low: JP¥1,156The company is down 18% from its price of JP¥1,406 on 20 November 2020. The Japanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.
Reported Earnings • Feb 17Full year 2020 earnings released: JP¥35.32 loss per share (vs JP¥35.81 loss in FY 2019)Full year 2020 results: Net loss: JP¥4.21b (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.